Stage III (T3N0M0) prostate cancer refers to those whose tumor is still confined to the prostate or has invaded the seminal vesicles or prostate envelope, but local lymph node metastasis has not yet been detected or confirmed. In the classification of prognostic risk factors for prostate cancer, most of them belong to intermediate or advanced risk level. Today, there are three issues of stage III prostate cancer that are of great clinical concern at home and abroad. Stage III prostate cancer is recognized as potentially curable at home and abroad. In short, if the approach is sound and appropriate, patients may be able to obtain early (stage II) treatment results. If it is easy for friends to understand, it can be described as “tug of war”. Currently, which is better: surgery, external radiotherapy, brachytherapy (radioactive particle implantation), argon helium cryoablation, and/or pharmacological endocrine therapy? It is controversial due to the lack of evidence-based medical evidence and no unified opinion or standard. The prognosis of stage III prostate cancer are medium and high risk patients, therefore, the vulnerability to recurrence and progression after treatment is a difficult issue in the field of treatment both at home and abroad. Since the treatment targets are those at high risk for clinical progression including local recurrence, diverse and comprehensive treatments are needed, but there are technical and strategic issues. Patients should understand that the treatment of stage III prostate cancer is still in the exploratory stage at home and abroad, therefore, it is not yet possible to evaluate which treatment is good and which is not. However, based on our long-term clinical practice and knowledge and summary of stage III prostate cancer, based on our clinical research results and foreign literature, we suggest the following to our friends for reference in treatment selection only. 1. Preferred treatment methods and combined treatment issues (1) Prefer radical surgical operation. After surgery, wait for observation, and then implement radiotherapy if there is local recurrence; or elective radiotherapy after surgery; combined with drug endocrine therapy. (2) Cryotherapy is preferred (for those who are not suitable for surgery and want minimally invasive treatment). Take postoperative wait-and-see, and then administer radiotherapy if there is local recurrence; or postoperative elective radiotherapy. (3) Preferred radiotherapy. If there is local recurrence, salvage cryotherapy is used; combined with drug endocrine therapy. 2, adjuvant drug endocrine therapy problem Also known as hormone blocking method, it has replaced surgical testicular denervation surgery in foreign countries and is one of the important comprehensive treatment methods, but conversion to hormone non-dependent (treatment failure) within a certain period of time is almost inevitable. In order to delay the occurrence of non-dependent adverse events, intermittent (interval time) and crossover (alternating first, second and third line drugs) administration has been mostly advocated in recent years. According to the results of our study, only 11.1% (5/45) of the patients required drug endocrine therapy within 10 to 45 months after the use of single cryotherapy. Therefore, we believe that it is reasonable, effective and feasible to reserve the treatment space appropriately and give drug therapy when clinical progress is confirmed under the premise of effective treatment, which can help to delay the occurrence of drug non-dependence problems to the maximum extent. The latest foreign research results also support our view. Of course, T3b stage should be combined with pharmacological endocrine therapy. As the saying goes, there is no fear of firewood if you stay in the green hills. It is said that the continuous crossover, penetration and integration of medical science and modern high technology will certainly give rise to new treatment technologies and methods and constantly enrich the relevant treatment content. So, if you wait, you have a chance.